Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Diabetes / Metabolic Rheumatology Gastroenterology Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Phase I NCT05890729

A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis — Recruiting • Phase I • Respiratory / COPD / Asthma • NCT05890729.

📅 20 May 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase I
NCT ID
NCT05890729
Sponsor
Xentria, Inc.
Start
2023-11-10
ClinicaliQ Trial Snapshot
  • A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis — Recruiting • Phase I • Respiratory / COPD / Asthma • NCT05890729.
  • Sponsor: Xentria, Inc.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis

Eligibility Snapshot
  • :
  • Participant between 18 to 80 years (inclusive) of age. 2. Weighs between 45 kg and 160 kg (99 to 353 lbs) at Screening. 3. Diagnosis of pulmonary sarcoidosis (at least 6 months before Screening) using the 2020 American Thoracic Society (ATS) Clinical Practice Guideline (Crouser et al, 2020), the European Respiratory Society (ERS) or the WASOG criteria including a compatible clinical and radiologic presentation with other causes of granulomatous disease ruled out (cutaneous and ocular involvement permitted). 4. Modified Medical Research Conference (mMRC) Dyspnea Scale of ≥ 1. 5. Receiving treatment of 7.5 to 25 mg/day of oral prednisone, or equivalent, during the screening period and, at the determination of the investigator, is capable of undergoing the protocol specific corticosteroid taper regimen. 6. Receiving treatment with methotrexate, azathioprine, mycophenolate, leflunomide, chloroquine, or hydroxychloroquine for at least 3 months before Screening that has been at a stable dose for 4 weeks before Screening. All efforts should be made to maintain stable background therapy at the Screening dose through the intervention period at the Investigator's discretion. 7. PART A only: Willing to refrain from consumption of grapefruit or grapefruit juice [pomelos, exotic citrus fruits, or grapefruit hybrids] from screening…

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
2022 ERS/ESC Guidelines on Pulmonary Hypertension
Respiratory / COPD / Asthma · 30 Mar 2026
This ERS guideline addresses 2022 ERS/ESC Guidelines on Pulmonary Hypertension in Respiratory / COPD / Asthma. Use it to review current recommendation…
View guideline →
Guideline
2022 ERS Guidelines on Idiopathic Pulmonary Fibrosis
Respiratory / COPD / Asthma · 30 Mar 2026
Covers diagnostic criteria for idiopathic pulmonary fibrosis (IPF) including HRCT patterns • Provides recommendations for antifibrotic therapy and patient selection • Addresses…
View guideline →
Guideline
Idiopathic Pulmonary Fibrosis: Diagnosis and Management (NICE NG163)
Respiratory / COPD / Asthma · 27 Mar 2026
Suspect IPF in adults aged >50 presenting with unexplained progressive dyspnoea, cough, or fatigue with significant smoking history or occupational exposure, and…
View guideline →
Guideline
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils
Respiratory / COPD / Asthma · 26 Mar 2026
Dupilumab is recommended for maintenance treatment of uncontrolled COPD only in patients with blood eosinophil count ≥400 cells/μL, as this biomarker predicts…
View guideline →
Guideline
Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management (NICE NG115)
Respiratory / COPD / Asthma · 25 Mar 2026
Confirm COPD diagnosis with spirometry showing post-bronchodilator FEV1/FVC ratio
View guideline →
Clinical Brief
Amiodarone: reminder of risks of treatment and need for patient monitoring and supervision
Respiratory / COPD / Asthma · MHRA · 20 May 2026
Amiodarone carries serious risks of pulmonary, hepatic, and thyroid toxicity requiring regular patient monitoring and supervision throughout treatment Healthcare professionals must ensure…
View brief →